Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma | Zendy

Bernard Escudier | Zendy; Tim Eisen | Zendy; Walter M. Stadler | Zendy; Cezary Szczylik | Zendy; Stéphane Oudard | Zendy; M. Siebels | Zendy; Sylvie Négrier | Zendy; Christine Chevreau | Zendy; E Solska | Zendy; Apurva A. Desai | Zendy; Frédéric Rolland | Zendy; Tomasz Demkow | Zendy; Thomas E. Hutson | Zendy; Martin Gore | Zendy; Sara M. Freeman | Zendy; Brian Schwartz | Zendy; Minghua Shan | Zendy; Ronit Simantov | Zendy; Ronald M. Bukowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Author(s) -

Bernard Escudier,

Tim Eisen,

Walter M. Stadler,

Cezary Szczylik,

Stéphane Oudard,

M. Siebels,

Sylvie Négrier,

Christine Chevreau,

E Solska,

Apurva A. Desai,

Frédéric Rolland,

Tomasz Demkow,

Thomas E. Hutson,

Martin Gore,

Sara M. Freeman,

Brian Schwartz,

Minghua Shan,

Ronit Simantov,

Ronald M. Bukowski

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa060655

Subject(s) - sorafenib , medicine , placebo , hazard ratio , renal cell carcinoma , clinical endpoint , rash , oncology , interim analysis , adverse effect , surgery , gastroenterology , confidence interval , randomized controlled trial , hepatocellular carcinoma , pathology , alternative medicine

We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research